Why Farbe Firma is the Top Manufacturer of Xanthinol Nicotinate Injection
- Maulik Sudani
- 9 hours ago
- 9 min read
Last Updated: July 2, 2026
TL;DR: Xanthinol Nicotinate Injection - a sterile aqueous solution of xanthinol nicotinate, a peripheral and cerebral vasodilator that combines a theophylline-type xanthine moiety with nicotinic acid (niacin) in a single molecule, supplied commonly as a 300 mg/2 mL (150 mg/mL) solution in a glass ampoule for intramuscular or slow intravenous use - is the vasodilator clinicians use to improve microcirculation and blood flow in peripheral and cerebral circulatory disorders such as intermittent claudication, arteriosclerosis obliterans and cerebrovascular insufficiency. Because a parenteral vasodilator solution is injected into muscle or vein, each ampoule must deliver a sterile, clear, correctly concentrated solution, with the dual-moiety assay and related substances, solution pH, colour and clarity, particulate and endotoxin, a validated sterilisation route and verified container-closure integrity all mattering to potency and safety. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Xanthinol Nicotinate Injection at our Gujarat, India facility and supplies it to vascular-medicine, neurology and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Peripheral and cerebral vasodilator - xanthinol nicotinate combines a xanthine (theophylline-type) moiety with nicotinic acid, widening blood vessels, improving microcirculation and lowering blood viscosity, and Xanthinol Nicotinate Injection (a 300 mg/2 mL aqueous solution given intramuscularly or by slow intravenous infusion) demands a clear, correctly concentrated, particulate-free solution in every ampoule.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated compounding and ampoule filling, control of the dual-moiety assay and related substances by HPLC, solution pH, colour and clarity, particulate and endotoxin, validated terminal moist-heat sterilisation, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, forced-degradation data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile vasodilator ampoule contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Xanthinol Nicotinate Injection Demands a Premium Manufacturer
Xanthinol Nicotinate Injection holds an established place in vascular medicine across many markets. It is the therapy a clinician turns to when a patient's problem is poor blood flow - in peripheral vascular disease and intermittent claudication, in arteriosclerosis obliterans and Raynaud's-type circulatory disorders, in the cerebrovascular insufficiency of older patients, and in some inner-ear and retinal vascular disorders. Xanthinol nicotinate is an unusual molecule: it links a theophylline-type xanthine, which relaxes vascular smooth muscle and raises intracellular cyclic AMP, with nicotinic acid, itself a vasodilator, so that a single injection widens peripheral and cerebral vessels, improves microcirculation, increases tissue oxygen delivery and improves the flow properties of the blood. What makes the parenteral form distinctive is that it delivers this vasodilator directly by injection, into muscle or by slow intravenous infusion, for a faster and more complete effect than the oral route - so the prescriber depends on an accurately concentrated, sterile, clear solution that behaves predictably at the bedside.
That clinical reality places real demands on the manufacturer. Xanthinol Nicotinate Injection is presented as a sterile aqueous solution - for example 300 mg in a 2 mL glass ampoule, a 150 mg/mL solution given intramuscularly or diluted for slow intravenous infusion - so the concentration must be exact and the fill accurate so that each ampoule provides the labelled dose. Although xanthinol nicotinate is a freely water-soluble and comparatively stable small molecule, the injection still poses specific quality challenges. Because the drug is a single molecule carrying two distinct pharmacophores, the xanthine and the nicotinate, the assay must confirm the intact molecule and its content and the related-substance methods must detect degradation of either moiety, all by validated HPLC. The solution must be crystal clear and essentially colourless, because a parenteral solution is inspected for clarity and colour and any haze or discoloration signals a problem, and it must be free of visible and sub-visible particulate. The product is a solution that generally tolerates validated terminal moist-heat sterilisation, which - properly designed and validated - gives the highest sterility assurance, but the sterilisation cycle must still be shown not to degrade the molecule or shift the pH or colour. Solution pH is controlled within the range where the molecule is most stable, photostability is characterised because the nicotinate moiety can be light-sensitive, endotoxin is held very low and container-closure integrity is assured for the glass ampoule. The label carries the intramuscular and slow-intravenous administration instruction and the expected transient flushing and warmth of the nicotinic-acid component. Choosing a Xanthinol Nicotinate Injection manufacturer that treats the dual-moiety assay, solution clarity and the validation of terminal sterilisation as core disciplines is what protects the patient at the point of care.
What Sets a World-Class Xanthinol Nicotinate Injection Manufacturer Apart
A world-class manufacturer of Xanthinol Nicotinate Injection invests in three areas that weaker suppliers underfund: precise, validated control of the dual-moiety assay and related substances by HPLC - confirming the intact xanthinol nicotinate molecule and detecting degradation of either the xanthine or the nicotinate part - which this combination molecule demands; a robust, validated terminal moist-heat sterilisation process built around a solution that must stay clear, colourless and full-strength through the autoclave; and tender-ready dossier support, including the stability, photostability and sterilisation data, for a vascular-medicine product procured through hospital-pharmacy and ministry-of-health channels. It starts with the raw materials - pharmacopoeial or well-characterised xanthinol nicotinate drug substance of controlled purity, water for injection, pH-adjusting agents and, where used, an antioxidant or tonicity agent, each sourced from qualified, audited suppliers with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production. Because the value of the product is a precise, stable dose of an intact vasodilator molecule, the assay, related-substance and stability data are treated as central evidence rather than supporting annexes.
Compounding and filling then have to build - and defend - a clear, full-strength solution. The drug is dissolved in water for injection, the pH adjusted into its stable window, the solution polished by filtration to remove particulate, and, where oxidation of the nicotinate is a concern, the operation is protected as required. The solution is passed through a sterilising-grade filter and filled into glass ampoules under ISO Class 5 conditions, the ampoules sealed and terminally sterilised by a validated moist-heat cycle locked into the master batch record, giving a robust sterility assurance level for the solution presentation. Filled units are 100 % inspected for fill, seal, clarity, colour and particulate; in-process and release testing confirm the xanthinol nicotinate assay and concentration, the related-substance profile of both moieties by HPLC, solution pH, colour and clarity against defined limits, visible and sub-visible particulate matter, deliverable volume, and that endotoxin is held well within limits so the solution is safe for intramuscular or intravenous use. Because the product is a terminally sterilised solution whose potency depends on an intact molecule, the assay, the related substances, the pH and the colour are confirmed together, before and after the sterilisation cycle, so the solution that leaves the plant is the same clear, colourless, correctly concentrated solution the specification requires - with no haze, no discoloration and no out-of-limit degradation in the ampoule across shelf life.
Quality Systems Behind Every Xanthinol Nicotinate Injection
Every Farbe Firma Xanthinol Nicotinate Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of xanthinol nicotinate against reference standards, control of related substances covering both the xanthine and the nicotinate moieties, solution pH, colour and clarity of solution against defined limits, deliverable volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the glass ampoule. Certificates of analysis are issued with full traceability back to each drug-substance lot, the primary-packaging lot and the qualified person responsible for release. Because the product is terminally sterilised, the assay, the related substances and the clarity are qualified both before and after the sterilisation cycle so the molecule's stability to heat is demonstrated rather than simply assumed.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated terminal-sterilisation and ampoule-filling equipment with 100 % inspection, sterilising-grade filtration with filter-integrity testing, controlled compounding and holding, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because a parenteral vasodilator is given directly into muscle or the bloodstream and its potency and safety depend on an intact, correctly concentrated molecule in a clear solution, we treat the assay, the related substances, the clarity, the pH and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under ICH Q1A long-term and accelerated conditions and ICH Q1B photostability, with the assay, related substances, colour and clarity followed across the study, so the solution stays clear, colourless and within specification across the labelled shelf life, and the storage instructions on the label are supported by real data.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Xanthinol Nicotinate Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad vascular-medicine and general-injectables portfolio. For Xanthinol Nicotinate Injection specifically, we supply the peripheral-vasodilator solution as a 300 mg/2 mL (150 mg/mL) ampoule, together with other strengths and fill volumes, under WHO-GMP conditions, with country-specific strengths, fill volumes, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier - including the dual-moiety-assay, related-substance, stability, photostability, sterilisation and container-closure data package - ready to hand for registration and tender qualification. Buyers evaluating Xanthinol Nicotinate Injection can request the assay, related-substance and accelerated-stability summaries up front, which is often the deciding technical evidence for a solution injectable in hospital-formulary and ministry-of-health review, since it is the confirmed potency of an intact molecule and a validated sterility assurance that separate a dependable vasodilator injection from an unreliable one.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability data, ICH Q1B photostability data, forced-degradation packages, sterilisation and container-closure reports, translated package inserts and artwork - including the intramuscular and slow-intravenous administration instructions, the storage directions, and the expected transient flushing and warmth caution of the nicotinic-acid component - for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Xanthinol Nicotinate Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment schedule delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding, filling and sterilisation suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team - practising pharmacists and R&D scientists - can talk through xanthinol nicotinate sourcing and purity control, the design of a clear, pH-stable dual-moiety vasodilator solution, the dual-moiety assay and related-substance strategy by HPLC, the validation of the terminal moist-heat sterilisation cycle, clarity, colour and particulate control, photostability, fill and concentration accuracy, endotoxin control, container-closure integrity and shelf-life choices in real detail. For a parenteral vasodilator where assay accuracy, solution clarity and molecular stability directly govern potency and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Xanthinol Nicotinate Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Xanthinol Nicotinate Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated compounding and ampoule filling, sterilising-grade filtration, validated terminal moist-heat sterilisation, 100 % inspection and continuous environmental monitoring.
Which strengths and presentations of Xanthinol Nicotinate Injection do you supply?
Our peripheral-vasodilator solution is available as a 300 mg/2 mL (150 mg/mL) aqueous solution in glass ampoules, with other strengths and fill volumes for intramuscular or slow intravenous use. Custom strengths, fill volumes, container formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Xanthinol Nicotinate Injection mainly used for?
Xanthinol Nicotinate Injection is a peripheral and cerebral vasodilator used for circulatory disorders such as intermittent claudication, arteriosclerosis obliterans, Raynaud's-type disorders and cerebrovascular insufficiency, improving microcirculation and blood flow. It is given intramuscularly or by slow intravenous infusion; Farbe Firma verifies the assay, related substances, pH, colour and clarity, particulate matter and endotoxin at release so each ampoule delivers a clear, full-strength solution. The transient flushing and warmth from the nicotinic-acid component is expected and is noted on the label.
Can Farbe Firma support country-specific registrations for Xanthinol Nicotinate Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability data, ICH Q1B photostability data, related-substance and forced-degradation packages, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Xanthinol Nicotinate Injection contract manufacturing?
MOQs vary by strength, fill volume, label complexity and dossier requirements. For our ampoule solution presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments